Nutra Pharma Corp.
NPHC
$0.00
$0.00100.00%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 109.50K | 88.50K | 72.70K | 135.10K | 139.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 109.50K | 88.50K | 72.70K | 135.10K | 139.80K |
| Cost of Revenue | 38.80K | 33.60K | 37.50K | 41.40K | 24.80K |
| Gross Profit | 70.70K | 54.80K | 35.20K | 93.70K | 115.00K |
| SG&A Expenses | 255.40K | 274.30K | 330.50K | 234.00K | 280.70K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 294.20K | 308.00K | 368.00K | 275.40K | 305.60K |
| Operating Income | -184.80K | -219.50K | -295.30K | -140.20K | -165.80K |
| Income Before Tax | -260.70K | -367.10K | -426.90K | -243.10K | -278.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -260.70K | -367.10K | -426.90K | -243.10K | -278.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -260.70K | -367.10K | -426.90K | -243.10K | -278.50K |
| EBIT | -184.80K | -219.50K | -295.30K | -140.20K | -165.80K |
| EBITDA | -182.90K | -217.60K | -293.40K | -138.40K | -160.30K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 7.66B | 7.66B | 7.64B | 7.62B | 7.61B |
| Average Diluted Shares Outstanding | 7.66B | 7.66B | 7.64B | 7.62B | 7.61B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |